We previously found that ABX treatment reduces GFAP+ astrocytes in male APPPS1-21 mice at 9 weeks and 3 months of age, suggesting that the GMB plays a role in regulating reactive astrocytosis in response to amyloidosis (9). This evidence concerns the gene GFAP and amyloidosis.